Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : NS Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Option Care Health has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy.
Brand Name : Viltepso
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 02, 2020
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : NS Pharma
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?